新股消息 | 传肿瘤药厂德昇济医药拟赴港上市 目标集资2亿美元

Core Viewpoint - Deshengji Pharmaceutical, a developer of cancer treatment drugs, plans to go public in Hong Kong with a fundraising target of $200 million, currently in discussions with investment banks [1] Group 1: Company Overview - Deshengji Pharmaceutical has developed a next-generation cancer drug that has shown significant efficacy in inhibiting solid tumors triggered by specific gene mutations, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer [1] Group 2: Funding and Investment - In December of last year, Deshengji Pharmaceutical completed a $108 million Series B financing round, with participation from IDG Capital and Songqing Capital, along with continued investments from WuXi AppTec's venture capital fund, Temasek, Sequoia China, Matrix Partners, and Medicxi [1] - Bo Yu Capital is also noted as one of the shareholders [1] Group 3: Clinical Research - The funds from the Series B financing are intended to support the global Phase III pivotal clinical study of the core candidate drug elisrasib (D3S-001), evaluating its application in patients with KRAS G12C mutation tumors as both a monotherapy and in combination therapy, covering regions including the United States, China, and the European Union, to advance global registration submissions [1]